Topical androgen receptor antagonist
A topical non-steroidal AR antagonist developed for androgenetic alopecia; never advanced to commercial development but widely used as a research compound.
Abstract
RU58841 (PSK3841; CAS 154992-24-2; molecular formula C17H18F3N3O3; molecular weight 369.34) is a non-steroidal androgen receptor antagonist developed at Roussel-Uclaf (now Sanofi) in the 1990s as a topical treatment for androgenetic alopecia. The compound is structurally a hydantoin and binds the AR with sufficient affinity to compete with DHT in scalp tissue. Topical application allows local AR antagonism in hair follicles with minimal systemic absorption, theoretically avoiding the sexual side effects of systemic 5AR inhibitors. Phase 1 and 2 trials demonstrated efficacy in slowing or reversing scalp hair loss. Development was discontinued at Roussel-Uclaf (subsequent corporate merger and prioritization). The compound entered the research-grade and DIY hair loss community via the published patents and has remained in informal use without regulatory approval. Used as a reference topical AR antagonist in dermatologic and androgen pharmacology research.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.